BRET¹-assay using the FDSS/µCELL imaging plate reader

Introduction

The GPCRs represent the largest family of cell surface receptors and are the main target for drugs available on the pharmaceutical market. To prevent receptors from both acute and chronic overstimulation, GPCR activity is regulated by an intensively studied mechanism called desensitization or internalization ⁽¹⁾.

Following ligand exposure, arrestins interact with phosphorylated GPCRs, uncoupling them from their cognate G protein, blocking further activation and promoting endocytosis ⁽²⁾. Interaction between receptors and β -arrestins is a measurable functional event in the GPCR-mediated signaling cascade. The biophysical technique named Bioluminescence Resonance Energy Transfer (BRET) has been widely used to monitor and quantify agonist-promoted β -arrestin recruitment ⁽³⁾, including high throughput screenings ⁽⁴⁾. For the first time, Pierre Fabre Research Institute presents this BRET¹ application on the FDSS/µCELL imaging plate reader (HAMAMATSU PHOTONICS) by monitoring the activity of the dopaminergic D2 receptor (short splice form), a prototypic and well characterized GPCR.

Experimental procedure

Rluc8 tagged-D2s receptor (C-terminal) and eYFP-tagged β -arrestin2 (N-terminal) were transfected into CHO cells, and 36 hours after transfection, cells were starved overnight (16 hours) in serum-free medium. The next day, cells were washed twice with PBS plus glucose 1 g/l, detached with PBS plus 3 mM EDTA and resuspended in PBS plus glucose 1 g/l. A Dc protein measurement assay (Bio-Rad) was performed according to the manufacturer's protocol. For BRET monitoring, cells were then distributed (70 µg per well, about 4x105 cells) in flat and white clear-bottom 96-well microplates (Costar, ref. #3903) and incubated during 10 minutes in the presence or absence of various ligands before signal collection. BRET between Rluc8 and eYFP was measured 9 minutes after the addition of the Rluc8 substrate coelenterazine h (5 µM final) (Promega). The BRET¹ signals were calculated by the ratio of emission of eYFP (516 nm-556 nm) to Rluc8 (460 nm-500 nm). BRET signals were collected by the FDSS/µCELL (HAMAMATSU PHOTONICS), a new imaging plate reader for kinetic cell-based assays .It can be equipped with one injection head (96, 384) and enables simultaneous injection and detection of all the wells (Cf. Fig 1).





The antagonist Haloperidol fully reverses the BRET signal induced by dopamine (a). The stimulation by dopamine is dose-dependent (b). Dopamine efficacy can be discriminated from others compounds activity (c) (Cf. Fig 2).



Fig. 2: Agonist-induced β-arrestin recruitment to D2s-R. Data represent the mean ± s.e.m. of at least 3 independent experiments.

Conclusions

This work confirms the ability of FDSS/µCELL to monitor protein-protein interactions, using BRET¹ technology. The main advantages of the FDSS/µCELL are its capability dispensing compounds and reading the light emitted simultaneously from the entire 96 well plate, thus allowing potentially HTS. Moreover, the switch time between the two filters for light emission readings is shorter than for the main other devices, which is a precious advantage for BRET measurements. The next step is to validate BRET² screening method, more sensitive and suitable for small distance changes.

Biblio

- (1) Ferguson S.S.G. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53, 1-24 (2001)
- (2) Pierce K.L., Lefkowitz R.J. Classical and new roles of β-arrestins in the regulation of G-protein-coupled receptor. Nat Rev Neurosci 2, 727-33 (2001)
- (3) Berglund M.M., Schober D.A., Statnick M.A., McDonald P.H., Gehlert D.R. The use of bioluminescence resonance energy transfer 2 to study neuropeptide Y receptor agonist-induced βarrestin 2 interaction. J Pharmacol Exp Ther 306, 147-156 (2003)
- (4) Hamdan F.F., Audet M., Garneau P., Pelletier J., Bouvier M. High-throughput screening of G-protein coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based β-arrestin2 recruitment assay. J Biomol Screen 10, 463-75 (2005)

★ FDSS is registered trademark of Hamamatsu Photonics K.K. (China, France, Germany, Italy, Japan, U.K., U.S.A.)

- * Product and software package names noted in this documentation are trademarks or registered trademarks of their respective manufacturers.
- Subject to local technical requirements and regulations, availability of products included in this promotional material may vary. Please consult your local sales representative.
- Information furnished by HAMAMATSU is believed to be reliable. However, no responsibility is assumed for possible inaccuracies or omissions.
 Specifications and external appearance are subject to change without notice.

© 2014 Hamamatsu Photonics K.K.

HAMAMATSU PHOTONICS K.K. www.hamamatsu.com

HAMAMATSU PHOTONICS K.K., Systems Division

812 Joko-cho, Higashi-ku, Hamamatsu City, 431-3196, Japan, Telephone: (81)53-431-0124, Fax: (81)53-435-1574, E-mail: export@sys.hpk.co.jp

U.S.A.: Hamamatsu Corporation: 360 Foothill Road, Bridgewater, N.J. 08807-0910, U.S.A., Telephone: (1)908-231-0960, Fax: (1)908-231-0124, FAX. (01)52-453-0124, Fax. (02)52-453-0124, Fax. (02)52-453-

China: Hamamatsu Photonics (China) Co., Ltd.: B1201 Jiaming Center, No.27 Dongsanhuan Beilu, Chaoyang District, Beijing 100020, China, Telephone: (86)10-6586-6006, Fax: (86)10-6586-2866 E-mail: hpc@hamamatsu.com.cn

FEB/2014 IP Created in Japan (PDF)

FDSS Application Note No.23